AstraZeneca's Fasenra (bevacizumab) is set to challenge GSK’s Nucala (mepolizumab) in eosinophilic granulomatosis with ...

AstraZeneca’s asthma drug Fasenra also works in a group of rare diseases that can lead to potentially fatal organ damage, a mid-stage trial has shown. Results of the phase 2 trial, published in ...

But there is increasing competition in the asthma market, with AstraZeneca’s Fasenra (benralizumab) the latest in a new wave of injected therapies, along with GlaxoSmithKline’s Nucala and Teva ...

Pulmicort sales declined 4% to $138 million. Fasenra recorded sales of $436 million in the quarter, up 13% year over year, ...

In this video, Juan Carlos Cardet, MD, of the University of South Florida (USF) Health Morsani College of Medicine in Tampa, ...

AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

The European Commission has approved the Committee for Medicinal Products for Human Use (CHMP) recommendation to change the terms of marketing authorization for Fasenra (benralizumab). It can now ...

New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroidsAstraZeneca’s Fasenra (benralizumab) ...

AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the current standard of care, GSK’s Nucala (mepolizumab), in patients ...

The European Commission (EC) has approved AstraZeneca's Fasenra (benralizumab) as an add-on therapy for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a ...

Shore Capital reiterated their buy rating on shares of AstraZeneca (LON:AZN – Free Report) in a research report report ...